transcript
show notes
Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big roles in major diseases, but they are unusually hard to target in a precise and safe way. Skape Bio is trying to change that by using artificial intelligence to design an emerging class of therapies known as mini proteins that can fit these receptors snugly and control them in ways traditional drugs often can’t. Christoffer Norn, co‑founder and CEO of Skape Bio, discusses how mini proteins share strengths of both small molecules and biologics while avoiding some of their weaknesses, why the company’s approach could open up new therapeutic opportunities, and how Skape Bio is building a broad pipeline of differentiated GPCR‑targeting therapies.
